Su­ven gets prod­uct patent from In­dia and Ja­pan

BioSpectrum (Asia) - - Company News -

In­dian drug firm Su­ven Life Sci­ences has been granted a patent each by In­dia and Ja­pan for a drug used in the treat­ment of neu­rode­gen­er­a­tive dis­eases.

Su­ven Life has been granted one prod­uct patent from In­dia and one prod­uct patent from Ja­pan cor­re­spond­ing to the New Chem­i­cal En­ti­ties (NCEs) for the treat­ment of dis­or­ders as­so­ci­ated with neu­rode­gen­er­a­tive dis­eases. The patents are valid till 2027 and 2032, re­spec­tively.

The granted claims of the patents are be­ing de­vel­oped as ther­a­peu­tic agents and are use­ful in the treat­ment of cog­ni­tive im­pair­ment as­so­ci­ated with neu­rode­gen­er­a­tive dis­or­ders like Alzheimer’s dis­ease, at­ten­tion de­fi­cient hy­per­ac­tiv­ity dis­or­der (ADHD), Hunt­ing­ton’s dis­ease, Parkin­son’s and Schizophre­nia.

The com­pany is very pleased by the grant of these patents for the pipe­line of mol­e­cules in CNS (cen­tral ner­vous sys­tem) arena that are be­ing de­vel­oped for cog­ni­tive dis­or­ders with high un­met med­i­cal need with huge mar­ket po­ten­tial glob­ally.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.